A Single Dose Escalation Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of SSS17 in Chinese Healthy Subject
Latest Information Update: 07 Mar 2022
At a glance
- Drugs SSS 17 (Primary)
- Indications Anaemia
- Focus Adverse reactions; First in man
- Sponsors Shenyang Sunshine Pharmaceutical
- 26 Mar 2020 New trial record